Royal Bank of Canada
MENS

Royal Bank of Canada’s Jyong Biotech MENS Stock Holding History

Royal Bank of Canada’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Buy
+266
New +$651 ﹤0.01% 7007

Other funds holding MENS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada's MENS Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in Jyong Biotech (MENS) in Q1 2026: 266 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #7007 among its holdings.

17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

  • Royal Bank of Canada held 266 shares of Jyong Biotech worth $1K as of Q1 2026.
  • Jyong Biotech was a new Royal Bank of Canada position in Q1 2026.
  • Jyong Biotech made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7007 holding.
  • 17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.